London-listed mineral sands explorer Capital Metals (LON: CMET) is projected to reach breakeven within two years, with analysts forecasting a first profit in 2028. The debt-free company's path hinges on achieving a steep annual growth rate amid its investment phase in UK and Sri Lankan projects.
Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.
A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.
Despite a weaker-than-expected volume environment, Norfolk Southern reported in-line cost performance for Q4 and highlighted significant strides in operational safety and efficiency. Executives pointed to a pivotal year of structural change while outlining cost and capital expenditure guidance for 2026.
Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.
National Fuel Gas (NFG) reported robust first-quarter earnings, driven by a 29% surge in upstream EBITDA. Executives highlighted progress on pipeline expansions, strategic hedging against volatile gas prices, and the planned acquisition of CenterPoint's Ohio utility, while reaffirming full-year guidance.
Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
DA Davidson joins Morgan Stanley in lowering price targets for language-learning app Duolingo, citing data suggesting daily active user growth may fall short of expectations despite a strong start to the year.
Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
Mizuho Securities dramatically raised its price target on SanDisk, forecasting a severe NAND flash memory shortage driven by explosive AI server demand and constrained production capacity through 2027.
NextPower Inc. sees its price target raised by TD Cowen following a robust third-quarter earnings beat and a landmark joint venture in Saudi Arabia, signaling growing confidence in the solar technology firm's trajectory.
